text
stringlengths 0
197k
|
|---|
* Complete pre-game questionnaires |
* Play either Hello or Table Topics game |
* Complete post-game questionnaires |
* Participate in a focus group |
* Complete a telephone follow up interview 1-4 months after their event |
This study is a continuation of NCT06028152. conditions: Breast Cancer conditions: Lung Cancer conditions: Genito-Urinary Cancer conditions: Colorectal Cancer conditions: Gastric Cancer conditions: Pancreatic Cancer conditions: Liver Cancer conditions: Head and Neck Cancer conditions: Melanoma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: INVESTIGATOR count: 32 type: ESTIMATED name: Hello for Cancer game name: Table Topics game measure: Feasibility and Acceptability of modified Hello game measure: Healthcare Utilization measure: Advance Care Planning Engagement Measure measure: Advance Care Planning Surrogate Decision Maker Engagement Measure measure: Satisfaction of Intervention Measure measure: Acceptability of Intervention Measure measure: Preliminary efficacy of Hello on ACP behaviors. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Penn State Cancer Institute city: Hershey state: Pennsylvania zip: 17033 country: United States name: Michael Hayes, PhD role: CONTACT phone: 717-531-8521 email: [email protected] name: Michael Hayes, PhD role: SUB_INVESTIGATOR name: Monika Joshi role: SUB_INVESTIGATOR lat: 40.28592 lon: -76.65025 hasResults: False |
<|newrecord|> nctId: NCT06384404 id: 2023-14741 briefTitle: Upfront Surgical Resection for Osteosarcoma acronym: UFSR for OS overallStatus: RECRUITING date: 2024-03-25 date: 2027-12-31 date: 2029-12-31 date: 2024-04-25 date: 2024-04-25 name: Montefiore Medical Center class: OTHER briefSummary: The goal of this pilot study is to learn about patients with newly diagnosed osteosarcoma of an extremity, and whether surgically removing the tumor prior to the administration of any chemotherapy will improve functional outcomes. In order to learn about the patient's experience, the study team will administer questionnaires to the patient and surgeon at various timepoints to assess recovery and the function of the extremity. conditions: Osteosarcoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10 type: ESTIMATED name: Questionnaire measure: Change in Health-Related Quality of Life (HRQoL) score from Historical Controls measure: Event Free Survival sex: ALL minimumAge: 5 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Montefiore Medical Center status: RECRUITING city: Bronx state: New York zip: 10467 country: United States name: Rebecca Zylber role: CONTACT phone: 718-741-2356 email: [email protected] name: Alice Lee, M.D. role: PRINCIPAL_INVESTIGATOR name: David Geller, M.D. role: SUB_INVESTIGATOR lat: 40.84985 lon: -73.86641 hasResults: False |
<|newrecord|> nctId: NCT06384391 id: 4-2023-1730 briefTitle: Intestinal Ultrasound, Magnetic Resonance Enterography, and Conventional Assessment Tools Before and After Treatment of Intestinal Behcet's Disease overallStatus: RECRUITING date: 2024-04-30 date: 2025-06-30 date: 2025-12-31 date: 2024-04-25 date: 2024-04-25 name: Yonsei University class: OTHER briefSummary: Background: The "treat-to-target" approach has recently been adopted in the treatment of inflammatory bowel disease (IBD). The basic premise is to define specific measurable targets and then adjust treatment until these targets are achieved and maintained. According to the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)-Ⅱ statement published in 2021, the long-term treatment targets for IBD are clinical remission, endoscopic healing, absence of disability, restoration of quality of life, and normal growth in children. Symptomatic relief and normalization of serum and fecal markers were determined as short-term targets. Transmural healing in Crohn's disease and histological healing in ulcerative colitis are not formal targets but should be assessed as measures of the remission depth. |
While endoscopic examination assesses the mucosal inflammatory status of the bowel wall, transmural inflammatory status needs to be evaluated with ultrasound, computed tomography (CT), or magnetic resonance enterography (MRE). Ultrasound is advantageous as it does not utilize ionizing radiation and is less costly and uncomfortable for patients, allowing more frequent use. Recent studies suggest that intestinal ultrasound is beneficial in treatment response assessment and planning in patients with Crohn's disease and ulcerative colitis. However, there is a paucity of study regarding the effectiveness of intestinal ultrasound in management of intestinal Behcet's disease. Furthermore, despite its accuracy and comprehensive imaging capabilities without radiation risk, MRE has not been widely used in the diagnosis and follow-up of the patients with intestinal Behcet's disease, and no studies have reported changes in MRE findings after treatment. conditions: Intestinal Behcet Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 55 type: ESTIMATED measure: Accuracy of intestinal ultrasound in identifying endoscopic remission at 26 weeks after initiation of medical treatment measure: Accuracy of intestinal ultrasound in identifying clinical remission at 26 weeks after initiation of medical treatment measure: Accuracies of magnetic resonance enterography in identifying endoscopic and clinical remission at 26 weeks after initiation of medical treatment measure: Accuracies of magnetic resonance enterography in identifying endoscopic and clinical responses at 26 weeks after initiation of medical treatment sex: ALL minimumAge: 19 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yonsei University Health system, Severance Hospital status: RECRUITING city: Seoul zip: 03722 country: Korea, Republic of name: Hyun Kyung Yang role: CONTACT phone: 82-2-2228-7400 email: [email protected] lat: 37.566 lon: 126.9784 hasResults: False |
<|newrecord|> nctId: NCT06384378 id: FP00006640 briefTitle: Systemic and Central Inflammation in AD overallStatus: RECRUITING date: 2023-03-17 date: 2025-12-30 date: 2025-12-30 date: 2024-04-25 date: 2024-04-25 name: The Methodist Hospital Research Institute class: OTHER briefSummary: Inflammation could provide a new focus for therapeutic intervention. In this study, we will measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to measurements of brain glial activation obtained by positron emission tomography (PET). In addition, we will determine the effect of low-dose interleukin-2 (IL-2) immunotherapy, given over 22 weeks, on these inflammation biomarkers. conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: 11C-ER176 measure: Blood inflammation biomarker levels measure: CSF inflammation biomarker levels measure: Voxel-wise, regional and total brain TSPO VT/fP measured with 11C-ER176 PET sex: ALL minimumAge: 50 Years maximumAge: 86 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Houston Methodist Research Institute status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Alireza Faridar role: CONTACT phone: 713-441-1150 email: [email protected] lat: 29.76328 lon: -95.36327 hasResults: False |
<|newrecord|> nctId: NCT06384365 id: 706014-4 briefTitle: Interaction of Inflammation, Taste Perception and Preferences as a Function of Physical Activity and Body Composition overallStatus: RECRUITING date: 2024-04-15 date: 2024-09-30 date: 2025-04-30 date: 2024-04-25 date: 2024-04-29 name: University of Vienna class: OTHER briefSummary: The aim of this study is to investigate whether differences in taste perception and preference behavior can be attributed to inflammatory processes induced by physical activity. The focus will be on sweet taste and the perception of fat. A non-invasive, observational study design will be used. conditions: Taste, Altered studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 66 type: ESTIMATED name: Physical activity measure: Taste sensitivity measure: Taste preference measure: Body composition measure: Low-grade inflammation measure: Oxidative Stress measure: fungiform papillae density sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Christian Doppler Laboratory for Taste Research status: RECRUITING city: Vienna zip: 1090 country: Austria name: Barbara Lieder, PhD role: CONTACT phone: +431427770611 email: [email protected] lat: 48.20849 lon: 16.37208 hasResults: False |
<|newrecord|> nctId: NCT06384352 id: YL211-INT-101-01 briefTitle: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-05-08 date: 2027-04-07 date: 2029-04-07 date: 2024-04-25 date: 2024-04-29 name: MediLink Therapeutics (Suzhou) Co., Ltd. class: INDUSTRY name: Hoffmann-La Roche briefSummary: This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and RED will be determined. |
Part 2 is backfill enrollment part. We will further estimate the safety and efficacy of YL211 in patients with selected adcance tumor to select the RED(s) of YL211. |
Part 3 is dose-expansion part. In this part, we will further evaluate the safety and efficacy of YL211 at the MTD/RED(s) in patients with selected advanced solid tumors YL211 will be administered intravenously (IV) until criteria of treatment discontinuation are met. conditions: Advanced Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 155 type: ESTIMATED name: YL211 measure: To evaluate nature and frequency of AEs of YL211 in patients with advanced solid tumors according to NCI CTCAE version 5.0 measure: To evaluate nature and frequency of DLTs in part 1. measure: ORR assessed using RECIST version 1.1 measure: To determine the MTD and select the recommended expansion dose(s) (RED(s)) of YL211 in patients with advanced solid tumors measure: To characterize the AUC of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the Cmax of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the Ctrough of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the Tmax of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the CL of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the Vd of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the t1/2 of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To evaluate the anti-drug immune response after treatment with YL211 measure: To evaluate DCR of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate DoR of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate SD of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate TTR of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate PFS of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate OS of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate percent change in target lesion of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: Characterization of genomic alterations that are predictive of response to YL211 measure: The use of circulating tumor DNA (ctDNA) to monitor response to YL211 treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NEXT San Antonio city: San Antonio state: Texas zip: 78229 country: United States name: Site Coordinator role: CONTACT lat: 29.42412 lon: -98.49363 hasResults: False |
<|newrecord|> nctId: NCT06384339 id: ID-ClimAct-1 briefTitle: ID-ClimAct. Influence of Social Motives of Clients and Staff on the Social Climate of Secure Settings acronym: ID-ClimAct overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2024-09-20 date: 2024-10-20 date: 2024-04-25 date: 2024-04-29 name: University Psychiatric Clinics Basel class: NETWORK name: University of Basel briefSummary: The social climate in secure settings is an essential element to successful rehabilitation. Previous studies indicate that staff characteristics are a relevant factor contributing to a beneficial social climate. Yet, secure settings form a specific and challenging work environment. Staff members are faced with clients who present a variety of difficult emotional and behavioural problems. Social motives for caring and cooperation can be blocked in a threatening environment, favouring dysfunctional interpersonal dynamics between individuals. This observational study explores the reciprocal influences of social motives between clients and staff on the social climate within secure settings. conditions: Social Environment conditions: Correctional Institutions conditions: Rehabilitation of Criminals conditions: Social Dominance conditions: Interpersonal Relations studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED name: CSIV, Social motive name: Interpersonal messages and behavior name: CCS, Social motive measure: Social Climate Perception sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Psychiatric Clinics Basel, Clinic for Forensics city: Basel state: Basel-Stadt zip: 4002 country: Switzerland lat: 47.55839 lon: 7.57327 hasResults: False |
<|newrecord|> nctId: NCT06384326 id: bagattoni3 briefTitle: Parental Perceptions and Acceptance of Silver Diamine Fluoride in Spain and Italy acronym: SDF overallStatus: COMPLETED date: 2020-09-01 date: 2023-07-01 date: 2023-08-01 date: 2024-04-25 date: 2024-04-25 name: University of Bologna class: OTHER briefSummary: Assessing parental aesthetic acceptability of Silver Diamine Fluoride (SDF) staining is crucial for its potential implementation in paediatric dentistry. This study represents the third part of a wider project initially focused on evaluating SDF aesthetic acceptability in Italy, then comparing it between Spanish and Italian parents conditions: Comparative Study conditions: Aesthetic Perception conditions: Acceptability conditions: SDF studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 501 type: ACTUAL measure: Comparison of SDF's overall acceptance between Spanish and Italian parents measure: Comparison of SDF's specific acceptability in different scenarios of child's behavior between Spain and Italy measure: Parental overall acceptability of SD staining according to demographic background sex: ALL maximumAge: 12 Years stdAges: CHILD facility: Servizio di Assistenza Odontoiatrica per disabili in età evolutiva e di odontoiatria infantile city: Bologna zip: 40125 country: Italy lat: 44.49381 lon: 11.33875 hasResults: False |
<|newrecord|> nctId: NCT06384313 id: NL86266.068.24 briefTitle: Butyrate-enriched Triglyceride and Diabetes Prevention overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-09-01 date: 2027-09-01 date: 2024-04-25 date: 2024-04-25 name: Maastricht University Medical Center class: OTHER briefSummary: A body of animal studies as well as observational studies in humans demonstrated that butyrate is one SCFA that has pronounced positive effects on body weight control, inflammation, and insulin resistance. Even though the SCFA hexanoate is less researched, it has been shown to be involved in anti-inflammatory processes. Of note, acute human studies showed that fibre-induced metabolic improvements are linked to higher SCFA levels in the systemic circulation. We previously showed that a butyrate/hexanoate-enriched triglyceride oil enhanced systemic butyrate and hexanoate concentrations for a prolonged time. Yet, it remains to be determined whether a chronic increase in circulating butyrate and hexanoate concentrations translate into long-term benefits. We hypothesize that a chronic increase of butyrate/hexanoate in the circulation may improve host metabolism and metabolic health by improving adipose tissue function, reducing systemic lipid overflow and inflammation thereby increasing peripheral insulin sensitivity in individual with overweight/obesity and prediabetes. conditions: Type 2 Diabetes conditions: PreDiabetes conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: butyrate/hexanoate-enriched triglycerides measure: Peripheral insulin sensitivity measure: hepatic insulin sensitivity measure: adipose tissue insulin sensitivity measure: Energy expenditure (indirect calorimetry) measure: Substrate oxidation (indirect calorimetry) measure: circulating SCFA measure: Faecal SCFA measure: Faecal microbiota composition measure: Circulating hormones such as insulin measure: Circulating metabolites such as glucose measure: body composition measure: body weight measure: Gut permeability sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06384300 id: BMSF briefTitle: Financial Incentives and Motivational Intervention to Improve Gastric Cancer Screening in China overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2027-01-31 date: 2027-07-31 date: 2024-04-25 date: 2024-04-25 name: Peking University class: OTHER briefSummary: Gastric cancer, also known as stomach cancer, is a serious disease that affects the stomach. It's one of the most common types of cancer, and sadly, many people die from it each year. But there's hope! We can catch gastric cancer early with a special test called endoscopy. This test helps doctors find cancer or pre-cancerous changes in the stomach early, when it's easier to treat. However, not enough people get this test, especially in places where healthcare isn't easily available. That's why we're doing this study. |
We want to find out if we can encourage more people to get the endoscopy test for gastric cancer. We're going to try two different ways to encourage people to get the test. First, we'll give some people money or other incentives to help cover the costs of getting the test. Second, we'll give others information and support to help them understand why the test is important and how it can help them. |
We'll be doing this study in two provinces in China, where gastric cancer is a big problem. We'll ask thousands of people to join the study, and we'll randomly assign them to one of the two groups. Then, we'll see if more people in one group get the endoscopy test compared to the other group. |
Our hope is that by finding out what works best, we can help more people catch gastric cancer early and get the treatment they need. This could save many lives and make a big difference in fighting this disease. conditions: Gastric Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 5000 type: ESTIMATED name: Financial Incentives name: Motivational Intervention name: Mixed Intervention measure: Primary Outcome 1 measure: Primary Outcome 2 measure: Secondary Outcome sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06384287 id: APHP231342 briefTitle: Peripheral Tissue Perfusion in Intensive Care acronym: INPPEREA overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-05 date: 2027-05 date: 2024-04-25 date: 2024-04-25 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Tissue perfusion has been identified as an early prognosis factor in patients admitted to intensive care. However, little is known about the effects of different hemodynamic interventions performed in clinical routine on peripheral tissue perfusion. |
The aim of this work is to study the kinetics of CRT and local skin blood flow following therapeutic intervention (fluid challenge, vasopressor or inotropic drug). conditions: Acute Circulatory Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 180 type: ESTIMATED measure: Skin blood flow variations measure: Capillary refill time measure: Mottling score measure: correlation between Skin blood flow and CRT (baseline and variations) measure: correlation between skin blood flow and Cardiac output measure: correlation between skin blood flow and mean arterial pressure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06384274 id: NEUniversity briefTitle: The Effect of Emotional Freedom Technique and Virtual Reality Glasses on Anxiety and Vital Signs overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2024-10-01 date: 2025-06-01 date: 2024-04-25 date: 2024-04-25 name: Necmettin Erbakan University class: OTHER briefSummary: The aim of the study was to examine the effects of the emotional freedom technique and virtual reality glasses applied to individuals receiving hyperbaric oxygen therapy for the first time on anxiety and vital signs. The hypotheses of this research are that there is a difference between the emotional liberation technique and virtual reality glasses groups and the control group in terms of anxiety and vital signs. conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 75 type: ESTIMATED name: Emotional Freedom Technique name: Virtual Reality Glasses measure: State Anxiety Inventory (STAI) measure: Blood Pressure measure: Pulse measure: Respiration measure: Body Temperature measure: Oxygen Saturation sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Gülsüm Gürsoy Açikgöz city: Konya state: Meram country: Turkey name: gülsüm GÜRSOY AÇIKGÖZ role: CONTACT phone: 05535553934 email: [email protected] lat: 37.87135 lon: 32.48464 hasResults: False |
<|newrecord|> nctId: NCT06384261 id: OV-AML-1231 briefTitle: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-01 date: 2027-06 date: 2024-04-25 date: 2024-04-25 name: OncoVerity, Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine? conditions: Leukemia, Myeloid, Acute studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: Cusatuzumab name: Venetoclax name: Azacitidine measure: Overall survival measure: Complete Remission rate (CR) measure: Event-free survival (EFS) measure: Composite CR rate (CRc) measure: Rate of CRh and CRi measure: Duration of CR measure: Time to first CR measure: Rate of minimal residual disease (MRD) negativity in patients achieving CR, CRh, or CRi measure: Proportion of participants proceeding to hematopoietic stem cell transplantation (HSCT) measure: OS in participants undergoing HSCT measure: Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuation measure: Incidence of dose modifications due to AEs measure: Number of participants with abnormal laboratory test results measure: Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) measure: Overall survival in subgroups of participants according to specified AML risk stratification models measure: Complete Remission rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06384248 id: LTC004-205 briefTitle: Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2025-12-28 date: 2025-12-28 date: 2024-04-25 date: 2024-04-25 name: Letolab class: INDUSTRY briefSummary: This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in patients with locally advanced or metastatic sarcoma；Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission or SD lasting \>12 weeks, proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004 conditions: Unresectable or Metastatic Sarcoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: LTC004 measure: ORR measure: DOR measure: PFS rate measure: OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06384235 id: LTC004-203 briefTitle: Phase II Clinical Study of LTC004 in Patients With mCRC overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2025-08-23 date: 2025-08-23 date: 2024-04-25 date: 2024-04-25 name: Letolab class: INDUSTRY briefSummary: This is a phase II clinical study to evaluate the safety and antitumor activity of LTC004 in patients with locally advanced or metastatic CRC，Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission，proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004 conditions: Locally Advanced or Metastatic CRC studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: LTC004 measure: ORR measure: DOR measure: PFS measure: OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06384222 id: 235513 id: NCI-2024-03418 type: REGISTRY domain: NCI Clinical Trials Reporting Program (CTRP) briefTitle: Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) MRI as a Response Monitoring Tool to Neoadjuvant Abiraterone overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2027-07-31 date: 2027-07-31 date: 2024-04-25 date: 2024-04-25 name: Ivan de Kouchkovsky, MD class: OTHER briefSummary: This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadjuvant therapy. conditions: High Risk Prostate Carcinoma conditions: Prostate Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: Abiraterone acetate name: Prednisone name: Hyperpolarized [1-13C] pyruvate (HP 13C) name: Magnetic Resonance Imaging (MRI) name: Non-investigational radical prostatectomy (RP) name: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT) measure: Mean changes in intratumoral KPL measure: Pathological response rate measure: Proportion of participants with treatment-related adverse events measure: Proportion of participants completing RP measure: Median Time to Biochemical Recurrence measure: Proportion of participants with a >=50% decline in PSA level from baseline (PSA50) response measure: Proportion of participants with a >=90% decline in PSA level from baseline (PSA90) response measure: Mean PSA nadir sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California, San Francisco city: San Francisco state: California zip: 94143 country: United States name: Maya Aslam role: CONTACT phone: 415-514-8987 email: [email protected] name: Ivan de Kouchkovsky, MD role: PRINCIPAL_INVESTIGATOR lat: 37.77493 lon: -122.41942 hasResults: False |
<|newrecord|> nctId: NCT06384209 id: FBplus2024 briefTitle: The Friendship Bench Plus Trial acronym: FB+ overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-12-28 date: 2027-02-28 date: 2024-04-25 date: 2024-04-25 name: University of Bern class: OTHER name: University of Zimbabwe name: Swiss National Science Foundation briefSummary: The goal of this randomised controlled trial is to enhance the Friendship Bench intervention with antidepressants in adults with moderate to severe depression. The main questions it aims to answer are: |
1. Is the combination of the Friendship Bench with nurse-led antidepressants prescribing superior to the Friendship Bench alone? |
2. What are the barriers and enablers for the prescription of antidepressants by non-specialists in primary care? |
Type of study: Randomized controlled superiority trial |
Participants will be randomly selected and allocated into the control arm or intervention arm. Participants in the control arm will receive six sessions of the Friendship Bench Problem Solving Therapy while those in the intervention arm will receive the Friendship Bench intervention plus Fluoxetine (Sertraline for breastfeeding women). conditions: Major Depressive Disorder conditions: Severe Depressive Episode Without Psychotic Symptoms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 296 type: ESTIMATED name: Friendship Bench intervention name: Antidepressants -Fluoxetine measure: Treatment response measure: Remission sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Zimbabwe city: Harare country: Zimbabwe name: Rukudzo Mwamuka, Mbchb,MMed(Psychiatry) role: CONTACT phone: +263777065549 email: [email protected] name: Jermaine Dambi, PhD role: CONTACT phone: +263773444911 email: [email protected] lat: -17.82772 lon: 31.05337 hasResults: False |
<|newrecord|> nctId: NCT06384196 id: PID2022-138902OB-I00 briefTitle: Identity-Based Transdiagnostic Therapy for Young People With Anxiety and Depression acronym: IBTTYOUNG overallStatus: NOT_YET_RECRUITING date: 2024-07-02 date: 2025-06-30 date: 2025-11-02 date: 2024-04-25 date: 2024-04-25 name: University of Barcelona class: OTHER name: Badalona Serveis Assistencials name: Nou Barris Mental Health Center briefSummary: Depression and anxiety are the most prevalent mental disorders among both the general population and young adults, and transdiagnostic treatments for these patients are mostly based on cognitive-behavioral therapy (CBT). Based on common (transdiagnostic) principles of treatment (e.g., emotional exposure), these approaches have proliferated and demonstrated their efficacy in comparison to disorder-specific treatments. Although there are a few transdiagnostic approaches for children and adolescents, we could not find anyone targeting young people. For this reason, we propose the Identity-Based Transdiagnostic Therapy (IBTT) as a new treatment modality ideally created to address the challenge of improving the outcomes of psychotherapy for young adults with anxiety and/or depression. The IBTT is a psychological treatment for emotional disorders specifically designed for the youths in terms of their attitudes to treatment (attractiveness, engagement), and highly personalized to their construal of self and others. This project will allow testing the hypothesis that a novel brief psychotherapeutic intervention, IBTT, will be more efficacious in the treatment of the anxiety and/or depression of young adults than the well-established CBT-based Unified Protocol. conditions: Depression conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The main study of this project proposal is a multi-center, single-blind, parallel-group randomized clinical trial (RCT) conducted in Catalonia (Spain). primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 138 type: ESTIMATED name: Identity-Based Transdiagnostic Therapy (IBTT) name: Unified Protocol measure: Depression, Anxiety and Stress Scales (DASS-21) measure: Clinical Outcomes in Routine Evaluation-Short Form B (CORE-SFB) measure: Mini International Neuropsychiatric Interview (MINI) measure: Session Rating Scale 3.0 (SRS 3.0) measure: Life Satisfaction Scale (LSS) measure: Self-Concept Clarity Scale (SCCS) measure: Rosenberg Self-Esteem Scale (RSES) measure: Metacognition Self-Assessment Scale (MSAS) measure: Problem definition form measure: Change Interview measure: Consumer Reports Effectiveness Scale (CRES-4) sex: ALL minimumAge: 16 Years maximumAge: 29 Years stdAges: CHILD stdAges: ADULT facility: Badalona Serveis Assistencials city: Badalona zip: 08911 country: Spain name: Irene Alvarez, PhD role: CONTACT email: [email protected] lat: 41.45004 lon: 2.24741 facility: Associació Centre Higiene Mental Nou Barris city: Barcelona zip: 08042 country: Spain name: Giuseppina Rametti, PhD role: CONTACT email: [email protected] lat: 41.38879 lon: 2.15899 hasResults: False |
<|newrecord|> nctId: NCT06384183 id: KS-1000 briefTitle: Kerecis Real World Registry overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-06 date: 2027-06 date: 2024-04-25 date: 2024-04-26 name: Kerecis Ltd. class: INDUSTRY briefSummary: Multi-center, observational (i.e., non-interventional), open-label, real-world Registry on the Use of Kerecis Devices conditions: Wounds conditions: Pressure Ulcer conditions: Diabetic Foot Ulcer conditions: Venous Leg Ulcer conditions: Surgical Wound conditions: Soft Tissue Reinforcement studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: OTHER count: 600 type: ESTIMATED name: Kerecis Fish Skin Graft measure: Fish Skin Graft Device Related failure measure: Fish Skin Graft Device related allergy measure: Target Wound Infection measure: Complete Wound Healing measure: Complete Wound Closure sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06384170 id: IRB00442113 briefTitle: Closed Loop Spinal Cord Stimulation for Neuromodulation of Upper Motor Neuron Lesion Spasticity acronym: CLONUS overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-01 date: 2026-05 date: 2024-04-25 date: 2024-04-26 name: Johns Hopkins University class: OTHER name: Saluda Medical Pty Ltd briefSummary: Spasticity is characterized by increased muscle tension and is a classic consequence of upper motor neuron (UMN) damage in the central nervous system, such as from stroke or trauma. Clinically, it presents as muscle resistance to passive stretching, along with clasp-knife rigidity, clonus, increased tendon reflexes, and muscle spasms. An imbalance of the descending inhibitory and muscle stretch reflexes is thought to be the cause of spasticity. Post-stroke spasticity is a common condition that occurs in 37.5-45% of cases in the acute stage and 19-57.4% in the subacute stage after a stroke. At 6 months post-stroke, spasticity develops in 42.6-49.5% of cases, and at one year, it affects 35-57.4% of individuals. In patients with cerebral palsy (CP), incidence is almost 80% while in those living with spinal cord injury the number approaches up to 93%. Traumatic brain injury (TBI) patients have a higher prevalence on initial admission to neurorehabilitation but one in three patients will have chronic spasticity. However, the Defense and Veterans Brain Injury Center report a rate of TBIs amongst deployed veterans to be around 11-23% mostly from blast and explosive trauma. |
There have been studies as early as the 1980s exploring the efficacy of SCS for spasticity control, however, the credibility of many of these studies is constrained due to an incomplete comprehension of spasticity's underlying mechanisms, outdated research methods, and early limitations in implantable device technology. Intrathecal pumps for baclofen have remained as the mainstay for refractory spasticity, however, it comes with associated risks such as chemical dependence leading to acute baclofen withdrawal and requiring frequent refill requirement. Most importantly, it does not yield functional improvement of muscle activity, just suppression of spasticity. Botox is also routinely used but due to heterogeneity in muscle involvement as well as variability in provider skill, results may be inconsistent and short-lasting, requiring frequent clinic visits for repeat injections to the affected muscle groups. SCS may be able to address that gap in spasticity management. conditions: Chronic Pain conditions: Spasticity as Sequela of Stroke conditions: Upper Motor Neuron Lesion studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 12 type: ESTIMATED name: Spinal Cord Stimulation- Closed loop measure: Pain as assessed by Visual Analog Score measure: Spasticity Reduction as assessed by the Modified Ashworth's Score measure: Short Form 36 Health Survey (SF-36) score measure: Medication Use measure: Health Status as assessed by the EuroQol 5 Dimension 5 Level (EQ-5D-5L) measure: Spinal cord neurophysiological wave morphology measure: Spinal cord neurophysiological Current (mA/mV) measure: Spinal Cord Neurophysiological Characteristic- Conduction Velocity (m/s) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Johns Hopkins Hospital city: Baltimore state: Maryland zip: 21287 country: United States lat: 39.29038 lon: -76.61219 hasResults: False |
<|newrecord|> nctId: NCT06384157 id: INDV-2000-201 briefTitle: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-08 date: 2025-09 date: 2024-04-25 date: 2024-04-29 name: Indivior Inc. class: INDUSTRY briefSummary: The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non opioid treatment. conditions: Opioid Use Disorder studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: This is a randomized, double-blind, placebo-controlled study where the investigator, assessor, sponsor and participant are masked. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 300 type: ESTIMATED name: INDV-2000 name: Placebo measure: Proportion (probability) of participants without treatment failure by the end of Week 12 (Day 85). measure: Proportion (probability) of visits with opioid abstinence while participants are on IMP alone. measure: Participant's percentage of visits with opioid abstinence during the whole study follow-up. measure: Incidence, severity and relatedness of adverse events, treatment-emergent adverse events, serious adverse events and events leading to discontinuation and deaths. measure: Opioid Craving Assessment measure: Cmax on Day 1 and Day 15/16 measure: Tmax on Day 1 and Day 15/16 measure: AUC0-24 on Day 1 and Day 15/16 measure: Cavg on Day 1 and Day 15/16 measure: Cmin on Day 1 and Day 15/16 measure: CL/F on Day 1 and Day 15/16 measure: Clinical Opiate Withdrawal Scale (COWS) score sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06384144 id: 23QC8155 briefTitle: Machine Learning Miscarriage Management Clinical Decision Support Tool Study acronym: MLMM overallStatus: RECRUITING date: 2023-01-01 date: 2024-06-01 date: 2026-06-01 date: 2024-04-25 date: 2024-04-25 name: Imperial College London class: OTHER briefSummary: Machine learning used to develop an algorithm to determine chance of success with expectant or medical management for an individual patient. Taking into account the following objective measures: |
* Demographics: Maternal Age, Parity |
* History: Previous CS, Previous SMM/MVA, Previous Myomectomy |
* Gestation by LMP |
* Presenting symptoms: Bleeding score, Pain score |
* USS Measurements: CRL, GS, RPOC 3 dimensions, Vascularity |
* Discrepancy between gestation by CRL and LMP |
Audit to collate 1000 cases and identify features contributing to an algorithm that can predict outcome of miscarriage management for individualized case management. conditions: Miscarriage in First Trimester studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED name: Expectant Management of First Trimester Miscarriage name: Medical Management of First Trimester Miscarriage measure: Machine learning predictive model development for miscarriage management outcomes. measure: Prospective audit to test and validate predictive model sex: FEMALE minimumAge: 16 Years maximumAge: 55 Years stdAges: CHILD stdAges: ADULT facility: Imperial College Heatlhcare NHS Trust status: RECRUITING city: London zip: W12 0HS country: United Kingdom name: Sughashini Murugesu role: CONTACT phone: 07988390772 email: [email protected] lat: 51.50853 lon: -0.12574 hasResults: False |
<|newrecord|> nctId: NCT06384131 id: ABI-4334-102 id: 2024-511051-18 type: EUDRACT_NUMBER briefTitle: A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-04-22 date: 2025-04-22 date: 2024-04-25 date: 2024-04-25 name: Assembly Biosciences class: INDUSTRY briefSummary: This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50 subjects, randomized 8:2 to receive ABI-4334 or placebo. conditions: Chronic Hepatitis B studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Triple (Participant, Care Provider, Investigator) whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 50 type: ESTIMATED name: ABI-4334 name: Placebo measure: Primary Outcome Measure measure: Maximum Plasma Concentration (Cmax) of ABI-4334 in subjects with cHBV measure: Minimum Plasma Concentration (Cmin) of ABI-4334 in subjects with cHBV measure: Area Under Plasma Concentration-Time Curve (AUC) of ABI-4334 in subjects with cHBV measure: Time to Maximum Plasma Concentration (Tmax) of ABI-4334 in subjects with cHBV measure: Elimination half-life (t1/2) of ABI-4334 in subjects with cHBV measure: To evaluate the changes in HBV DNA (IU/mL or Log IU/mL) in subjects with cHBV measure: Proportion of subjects with HBV DNA < lower limit of quantification (LLOQ) and/or limit of detection (LOD) measure: Mean time elapsed to subjects achieving HBV DNA < LLOQ and/or LOD sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06384118 id: YZUHL20220047 briefTitle: Effects of a Health Intervention on Hypoglycemic Coping : a Pilot Study overallStatus: COMPLETED date: 2023-08-01 date: 2024-01-17 date: 2024-01-17 date: 2024-04-25 date: 2024-04-25 name: Yating Liu class: OTHER briefSummary: From August 2023 to January 2024, 100 patients with type 2 diabetes who met the inclusion and exclusion criteria were selected from the endocrinology department of The purpose of this study was to construct a hypoglycemia coping intervention program for type 2 diabetic patients based on the IMB theory and to investigate the feasibility, acceptability, and initial effects of the program. conditions: Type 2 Diabetes Mellitus conditions: Hypoglycemia conditions: Health Education studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ACTUAL name: Impact of an IMB theory-based health education intervention on hypoglycemic coping in patients with type 2 diabetes: a pilot study measure: The hypoglycemic coping style measure: hypoglycemic fear behavioral measure: Hypoglycemia fear worry measure: Level of health information access behavior measure: Level of health beliefs measure: Level of diabetes knowledge sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ya ting Liu city: Yangzhou state: 未选择 country: China lat: 32.39722 lon: 119.43583 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-08-01 uploadDate: 2024-04-16T10:45 filename: Prot_SAP_000.pdf size: 233766 hasResults: False |
<|newrecord|> nctId: NCT06384105 id: PRDE1 briefTitle: Study of the Patient Radiation Dose During Five Endourological Procedures acronym: PRDE overallStatus: RECRUITING date: 2023-12-19 date: 2024-12-18 date: 2024-12-18 date: 2024-04-25 date: 2024-04-25 name: Universiteit Antwerpen class: OTHER briefSummary: In the medical world more and more procedures are performed with the use of ionizing radiation (x-ray), both diagnostic and therapeutic. The main and most known risk is the development of malignancies as a result of the use of ionizing radiation. |
Purpose of this study: To examine the patient radiation dose (PRD) if the frames per second (FPS) are set differently during the five most performed endourological procedures where fluoroscopy is used (insertion/replacement of ureteral stent, (mini-)percutaneous nephrolithotomy (PCNL/PNL), ureterorenoscopy (URS) and extracorporeal shock wave lithotripsy (ESWL/SWL)) and to propose an acceptable PRD for these procedures in a multicentric study. conditions: Radiation Exposure conditions: Urolithiasis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 870 type: ESTIMATED name: frames per second measure: Dose limit measure: Difference in PRD measure: PRD different centres measure: PRD difference complicated cases sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AZ Klina status: RECRUITING city: Brasschaat state: Antwerp zip: 2930 country: Belgium name: Vincent De Coninck, MD role: CONTACT phone: +32 3 650 50 56 phoneExt: +32 email: [email protected] lat: 51.2912 lon: 4.49182 facility: UZA status: RECRUITING city: Edegem state: Antwerp zip: 2650 country: Belgium name: Stefan De Wachter, MD role: CONTACT phone: +32 3 821 33 68 phoneExt: +32 email: [email protected] lat: 51.15662 lon: 4.44504 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-07-06 uploadDate: 2024-04-22T15:53 filename: ICF_000.pdf size: 735146 hasResults: False |
<|newrecord|> nctId: NCT06384092 id: NB240005-NB-V briefTitle: Process Validation in Dermatology: Assessing Methods for UV Exposure (Artificial Source vs. Sunlight) and Efficacy Evaluation of Anti-Tanning Agents overallStatus: COMPLETED date: 2024-03-07 date: 2024-03-13 date: 2024-03-13 date: 2024-04-25 date: 2024-04-29 name: NovoBliss Research Pvt Ltd class: OTHER briefSummary: The rationale of this study is to establish a robust method for assessing sun protection product efficacy in preventing erythema and tanning. Employing both artificial ultraviolet-A Irradiation and natural direct sunlight exposure, the investigation seeks to provide a reliable methodology, ensuring reproducibility and enabling a direct comparison between these methods. Meticulously determining optimal UV dosages, the study prioritizes inducing skin responses for evaluation while avoiding adverse effects like blistering. The localized validation of UV exposure techniques, tailored to the Indian population, contributes significantly to the field by addressing diverse skin types and environmental conditions. By incorporating both artificial and natural (direct sunlight) UV exposure methods, the study aspires to enhance the safety and effectiveness of future dermatological investigations, benefiting both the scientific community and the broader population. conditions: Skin Pigmentation studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Proof of science/concept primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 6 type: ACTUAL name: Test Sun Protection Cream name: Benchmark Sun Protection Cream measure: Changes in Melanine index using instrumental assessment measure: Change in erythema index using instrumental assessment measure: Change in skin erythema/dryness/wrinkles and oedema using draize scale sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: NovoBliss Research Pvt Ltd city: Gandhinagar state: Gujarat zip: 382421 country: India lat: 23.21667 lon: 72.68333 hasResults: False |
<|newrecord|> nctId: NCT06384079 id: STU00219828 briefTitle: Duration of Ureteral Rest Prior to Ureteral Reconstruction Surgery overallStatus: RECRUITING date: 2024-05 date: 2025-11 date: 2030-11 date: 2024-04-25 date: 2024-04-25 name: Northwestern University class: OTHER briefSummary: Our objective is to assess the effect of duration of ureteral rest, defined as time from conversion of ureteral stent to percutaneous nephrostomy, on stricture length prior to ureteral reconstruction surgery. conditions: Ureteral Stricture studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: Antegrade and retrograde pyelogram measure: Ureteral stricture length measured by antegrade or retrograde pyelogram measure: Ureteral Stricture Quality will be graded as either narrowed or obliterated segment. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Northwestern University status: RECRUITING city: Chicago state: Illinois zip: 60611 country: United States name: Emily Ji role: CONTACT phone: 312-695-8146 email: [email protected] name: Ziho Lee, MD role: PRINCIPAL_INVESTIGATOR lat: 41.85003 lon: -87.65005 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-10-25 uploadDate: 2024-03-01T13:40 filename: Prot_000.pdf size: 140931 hasResults: False |
<|newrecord|> nctId: NCT06384066 id: STU00219774 briefTitle: Mobile Health Application to Improve Patient Satisfaction After Urethroplasty overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2024-12 date: 2024-04-25 date: 2024-04-25 name: Northwestern University class: OTHER briefSummary: Create a custom urethroplasty mobile application that will guide patients through through the surgical process. conditions: Urethral Stricture studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 80 type: ESTIMATED name: GetWell Mobile Application name: Standard of Care measure: Improve patient satisfaction, education and reported outcomes measure: Change in rate of patient phone calls and messages measure: Rate of emergency department visits sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-10-04 uploadDate: 2024-03-01T13:15 filename: Prot_000.pdf size: 9077970 hasResults: False |
<|newrecord|> nctId: NCT06384053 id: SAHARA Trial briefTitle: Skin Cancer and Hyperthermia and Radiotherapy acronym: SAHARA overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-07-01 date: 2028-07-01 date: 2024-04-25 date: 2024-04-25 name: Kantonsspital Winterthur KSW class: OTHER name: Luzerner Kantonsspital briefSummary: The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC). conditions: Basal Cell Carcinoma conditions: Squamous Cell Carcinoma Skin conditions: Non-melanoma Skin Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined name: Radiotherapy (RT) measure: Local control measure: Analysis measure: Late toxicities measure: Quality of life assessment sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Kantonsspital Winterthur city: Winterthur state: Kanton Zuerich zip: 8401 country: Switzerland lat: 47.50564 lon: 8.72413 facility: Luzerner Kantonsspital city: Luzern zip: 6000 country: Switzerland name: Winfried Arnold, MD role: CONTACT lat: 47.05048 lon: 8.30635 hasResults: False |
<|newrecord|> nctId: NCT06384040 id: GR-2019-12370692 briefTitle: Immuno-based Profiling of knEe OA Patients to Predict reSponse to Regenerative Treatment acronym: IMPRESA overallStatus: RECRUITING date: 2021-11-01 date: 2023-09-04 date: 2024-10-30 date: 2024-04-25 date: 2024-04-25 name: Istituto Clinico Humanitas class: OTHER name: Istituto Ortopedico Rizzoli briefSummary: Osteoarthritis (OA) is a highly prevalent degenerative musculoskeletal disease and a major cause of chronic disability worldwide. Its multifactorial origin contributes to determine the heterogeneous phenotypes and one unmet need is the lack of biomarkers to predict the individual response. Platelet-rich-plasma (PRP) injection is a minimally invasive autologous blood-derived approach for which we plan to define specific knee profiles predictive of response. We will take advantage of a unique multidisciplinary approach aimed at analysing clinics, imaging, and biomarkers of associated with clinical response. We will focus on inflammatory (Wnt system, IL1 pathway, PTX3) and antioxidant (primarily, DPP3/Keap1/Nrf2) pathways. We foresee that our results will allow a better allocation of immunomodulatory and regenerative therapies for a personalized approach in knee OA thus maximising the effectiveness of the healthcare allocation. conditions: Osteoarthritis, Knee studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 105 type: ESTIMATED name: platelet-rich plasma knee injection measure: knee OA patients focusing on changes in Wnt and IL1-ß signalling and PTX3 expression measure: To assess the overall oxidative status and antioxidant capacity of the enrolled OA patients and its possible prognostic role with respect to response to PRP treatment sex: ALL minimumAge: 40 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto Clinico Humanitas status: RECRUITING city: Rozzano state: Milano zip: 20089 country: Italy name: Berardo Di Matteo role: CONTACT phone: 02 82241 email: [email protected] lat: 45.38193 lon: 9.1559 hasResults: False |
<|newrecord|> nctId: NCT06384027 id: VNI_USG_2024 briefTitle: Effects of Non-invasive Ventilation on Function Diaphragmatic and Caval Distension overallStatus: RECRUITING date: 2024-02-05 date: 2024-04-17 date: 2024-06-10 date: 2024-04-25 date: 2024-04-25 name: Federal University of Paraíba class: OTHER briefSummary: Introduction: Understanding how the applicability of non-invasive ventilation can directly affect the anatomy and diaphragmatic function, as well as the opening diameter of the inferior vena cava in healthy individuals is fundamental to knowing how this therapy can interfere with treatment results. Objective: Identify the acute effects of PEEP and ventilatory support pressure on thickening fraction, diaphragmatic mobility and vena cava distension in healthy people. Methods: This is a crossover, randomized study, blinded to the evaluator and the researcher responsible for the statistical analysis. Volunteers will undergo a NIV session, randomized into groups: CPAP, Bi-level and spontaneous breathing, without NIV support (control). The outcomes evaluated will be diaphragmatic ultrasound and inferior vena cava distensibility. The CPAP levels will be: 5, 10 and 15 cmH2O after 5 minutes of use and in the Bi-level group we will maintain the PEEP value at 5cmH2O and modify the pressure support values to the values: 5, 7 and 10 cmH2O pressure support, with all outcomes also being assessed after 5 minutes. Participants will remain in a supine position, with the right upper limb positioned behind the head, throughout the protocol and all measurements will be collected in the inspiratory and expiratory phases with volumes basal currents. For statistical analysis, intention-to-treat analysis will be employed and groups will be compared using Student's t-test, for continuous variables, or chi-square, for categorical variables. ANOVA split-plot, repeated measures for primary occurrences. Analyzes of covariance to identify differences between groups using baseline scores as covariates. Effect sizes and confidence intervals will be calculated using eta squared (η²). Expected results: Elucidate the effects of different blood pressure levels on diaphragmatic function and inferior vena cava distension. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This is a crossover, randomized study, blinded primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 100 type: ESTIMATED name: Non-invasive ventilation measure: Diaphragmatic thickening fraction measure: Diaphragmatic mobility measure: Ultrasound of inferior vena cava distension sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Federal University of Paraiba status: RECRUITING city: João Pessoa state: Paraiba zip: 58051-900 country: Brazil name: Eduardo França, PhD role: CONTACT phone: 5583996575859 lat: -7.115 lon: -34.86306 hasResults: False |
<|newrecord|> nctId: NCT06384014 id: 2024/56 briefTitle: Examining the Effect of Different Filling Techniques on Healing in Lesional Teeth overallStatus: RECRUITING date: 2024-01-01 date: 2024-08-01 date: 2026-01-01 date: 2024-04-25 date: 2024-04-25 name: TC Erciyes University class: OTHER briefSummary: Microorganisms are an important factor in the development of periradicular diseases. The goal of non-surgical endodontic treatment is to eliminate microorganisms and their byproducts from the root canal system and to create an effective barrier between the root canal system and surrounding tissues. If there is no healing in the periradicular tissues after non-surgical endodontic treatment or if retreatment becomes impossible, surgical endodontic treatment is required. Apical resection is a surgical technique that involves removing the root tip of the tooth and closing the apical portion of the root canal system. An ideal retrograde filling material should be non-toxic, non-carcinogenic and biocompatible. It must also have dimensional stability and sealing properties. Amalgam, glass ionomer cements, and zinc oxide-eugenol based materials have been used for root end fillings in periapical surgery, but the desired success was not achieved. Today, Mineral Trioxide Aggregate (MTA) is preferred as a retrograde filling material due to its superior sealing properties, ability to harden in the presence of blood and moisture, antibacterial effects, biocompatibility and radiopacity. |
In the researchers' study, the effect of apical resection after orthograde canal filling and retrograde canal filling during apical resection on postoperative recovery will be compared. In both canal filling techniques, Sure-Seal Root MTA (Sure Dent Corporation-Korea) will be used as the filling material. Sure-Seal Root MTA is a calcium silicate based paste that is typically pre-mixed and ready to apply, exhibits excellent physical properties and does not show shrinkage during the curing process. As the manufacturer states, it is hydrophilic, biocompatible, has ideal setting and working time. |
Our faculty has piezosurgical ultrasonics (Mectron ®, Grassobbio BG, Italy). After the root tip resection is performed, the retrograde cavity will be prepared with Woodpecker ultrasonic tips (Guilin, China) compatible with this device. In our study using these materials and devices, a comparative analysis of the effects of different canal filling techniques on lesion healing and improvement in clinical symptoms will be made. conditions: Apical Cyst studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: İki farklı grupta farklı kanal dolum teknikleri uygulandıktan sonra apikal rezeksiyon yapılarak lezyon iyileşmesinin değerlendirilmesi primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: retrograde and orthograde root canal filling measure: Comparison of lesion healing rate after apical resection using different root canal filling techniques sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erciyes Üniversitesi Diş Hekimliği Fakültesi status: RECRUITING city: Kayseri zip: 38039 country: Turkey name: ERASLAN AKYÜZ role: CONTACT phone: 4447138 phoneExt: 0352 email: [email protected] lat: 38.73222 lon: 35.48528 hasResults: False |
<|newrecord|> nctId: NCT06384001 id: STUDY00004032 briefTitle: Meditation for Older Adults With Chronic Low Back Pain overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-10 date: 2025-12 date: 2024-04-25 date: 2024-04-25 name: Florida State University class: OTHER briefSummary: This pilot randomized controlled trial aims to recruit 66 community-dwelling older adults with chronic low back pain and follow up them for 8 weeks. This study aims to test the preliminary effect of a mindfulness-based meditation (MBM) intervention on pain and symptoms among community-dwelling older adults with chronic low back pain, and also to test the effect of the MBM intervention on the host Gut-Brain Axis (GBA). conditions: Chronic Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 66 type: ESTIMATED name: Active MBM name: Sham MBM measure: Change in pain intensity and interference measure: Change in pain sensitivities measure: Change in pain modulation measure: Change in chronic pain self-efficacy measure: Change in anxiety measure: Change in cognitive complaints measure: Change in depression measure: Change in fatigue measure: Change in sleep disturbance measure: Change in pain-related cortical response measure: Measurement and comparison of fecal microbiota alpha diversity, beta diversity, and abundance of microbial taxa in the human gut measure: Chang in inflammatory cytokines sex: ALL minimumAge: 50 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383988 id: IRB000112187 id: NCI-2023-10870 type: OTHER domain: NCI Trial Identifier id: Lead Organization Identifier type: OTHER domain: WF-2301CD briefTitle: A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources acronym: CONNECT overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2025-10 date: 2026-01 date: 2024-04-25 date: 2024-04-25 name: Wake Forest University Health Sciences class: OTHER name: National Cancer Institute (NCI) briefSummary: Clinical trial that tests the feasibility of a web based caregiver support resource, along with caregiver navigation sessions for caregivers of patients with stage II-IV lung cancer. The Caregiver Oncology Needs Evaluation Tool (CONNECT) is a novel web-based intervention designed for the community oncology setting, to systematically connect lung cancer caregivers with tailored supportive care resources. Lung cancer caregivers provide critical and challenging care for their loved ones and are at risk for their own negative psychosocial and physical outcomes. Implementing the CONNECT program along with caregiver navigation may provide additional support to caregivers of patients with stage II-IV lung cancer. conditions: Stage II Lung Cancer conditions: Stage III Lung Cancer conditions: Stage IV Lung Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 240 type: ESTIMATED name: Support for Caregiver - Generic List name: Support for Caregiver - Personalized List name: Internet-Based Intervention - CONNECT name: Patient Navigation measure: Caregiver retention at 12 weeks measure: Caregiver accrual rate measure: Caregiver participation measure: Caregiver retention at 24 weeks measure: Caregiver acceptability measure: Average time (minutes) needed for training for Local Practice Referral Coordinator measure: Desired modality for training (e.g., live webinar, recorded video, paper materials) for Local Practice Referral Coordinator measure: Average time (minutes) needed to identify and enter local resources into the Caregiver Oncology Needs Evaluation Tool (CONNECT) database measure: Frequency of needed resource updates in the CONNECT database measure: Average time (minutes) spent by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm measure: Modality of contact (e.g. phone, virtual web meeting, email) made by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm measure: Number of contacts made by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm measure: Number of referrals facilitated by the Local Practice Referral Coordinator and Central Caregiver Navigator measure: Type of referrals (e.g., in person, online) facilitated by the Local Practice Referral Coordinator and Central Caregiver Navigator measure: Average time (minutes) needed to communicate for Central Caregiver Navigator and Local Practice Referral Coordinator measure: Modalities used for communication (e.g., phone, virtual web meeting, email) for Central Caregiver Navigator and Local Practice Referral Coordinator measure: Improvements for the future trial from Local Practice Referral Coordinator's perspectives from a survey at the end of the study measure: Patient accrual rate measure: Patient participation rate measure: Patient retention at 12 weeks measure: Patient retention at 24 weeks sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383975 id: CIV-24-01-045634 briefTitle: VEin of MArshall Ethanolization vs Extended Pulmonary Vein PULSEd Field Ablation After Failed PVI for Persistent AF acronym: VEMAPULSE overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2027-04-30 date: 2027-04-30 date: 2024-04-25 date: 2024-04-25 name: Sebastien Knecht class: OTHER name: Boston Scientific Corporation briefSummary: The goal of this clinical trial is to compare two ablation techniques to treat patients with persistent atrial fibrillation (irregular and often very rapid heart rhythm). An ablation is a procedure during which some scars are made on the inside of the heart to break up the electrical signals that cause the irregular heartbeat. In this trial researchers will compare a new technique, which uses tiny electric shocks to make the scars, to the standard technique, which uses heat. |
The main question the trial aims to answer is: |
• Does the new technique work as well as the standard technique to prevent the irregular heartbeat from returning within one year of the procedure? |
Participants will: |
* Undergo an ablation with either the new or the standard technique |
* Visit the hospital 1, 3, 6, 9 and 12 months after the procedure for a check-up |
* Wear a device to register their heart rhythm for 24 hours before the 3 month visit and for 72 hours before the 6, 9 and 12 month visit |
* Record their heart rhythm at home every week |
* Complete a questionnaire 3, 6, 9 and 12 months after the procedure conditions: Persistent Atrial Fibrillation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: Pulsed field ablation with posterior wall isolation name: Radiofrequency ablation and vein of Marshall ethanolization measure: Atrial tachyarrhythmia recurrence within 12 months measure: Safety and procedural related adverse event measure: Duration of the ablation procedure measure: Fluoroscopy time measure: Fluoroscopy dose measure: Effect of the procedure on quality of life measure: Incidence of repeat ablation measure: Unscheduled visits and hospitalization sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AZ Sint-Jan Brugge AV city: Brugge zip: 8000 country: Belgium name: Emma Christiaen role: CONTACT email: [email protected] name: Sébastien Knecht, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 51.20892 lon: 3.22424 hasResults: False |
<|newrecord|> nctId: NCT06383962 id: CP 21-001-UK02 briefTitle: Post-Market Data Collection to Evaluate the Performance of the Synergy Disc® overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2029-09-01 date: 2034-09-01 date: 2024-04-25 date: 2024-04-25 name: Synergy Spine Solutions class: INDUSTRY name: MCRA briefSummary: This is a real world data collection observational study at a single site. There are both prospective and retrospective cohorts. The study will examine the safety and effectiveness of the Synergy cervical disc system in patients with degenerative cervical disc disease. conditions: Cervical Degenerative Disc Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Synergy cervical spine disc replacement measure: Neck Disability Index (NDI) measure: Device Related or Device Procedure Related Adverse Events measure: Neck and Arm Pain Measurement measure: Patient Satisfaction measure: Motor and Sensory Function in the Arm measure: Nurick's Criteria measure: Odom's criteria sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Royal Orthopaedic Hospital city: Birmingham country: United Kingdom name: Sam Papadopoullos role: CONTACT email: [email protected] name: Timothy Knight, MD role: PRINCIPAL_INVESTIGATOR name: Shahnawaz Haleem, MD role: SUB_INVESTIGATOR lat: 52.48142 lon: -1.89983 hasResults: False |
<|newrecord|> nctId: NCT06383949 id: CP 21-001-IRE01 briefTitle: Real World Data Collection on the Synergy Disc overallStatus: RECRUITING date: 2024-02-23 date: 2028-02-23 date: 2033-02-23 date: 2024-04-25 date: 2024-04-25 name: Synergy Spine Solutions class: INDUSTRY name: MCRA briefSummary: This is a real world data collection observational study at a single site. There are both prospective and retrospective cohorts. The study will examine the safety and effectiveness of the Synergy cervical disc system in patients with degenerative cervical disc disease. conditions: Cervical Degenerative Disc Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Synergy Cervical Disc system measure: Neck Disability Index (NDI) measure: Device Related or Device Procedure Related Adverse Events measure: Neck and Arm Pain Measurement measure: Patient Satisfaction measure: Motor and Sensory Function in the Arm measure: Nurick's Criteria measure: Odom's criteria sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mater Misericordiae University Hospital status: RECRUITING city: Dublin country: Ireland name: Jake McDonnell, MD role: CONTACT email: [email protected] name: Joseph Butler, MD role: PRINCIPAL_INVESTIGATOR name: Stacy Darwish, MD role: SUB_INVESTIGATOR lat: 53.33306 lon: -6.24889 hasResults: False |
<|newrecord|> nctId: NCT06383936 id: FAST-K II briefTitle: FAldini Sport Total Joint Arthroplasty-Knee II acronym: FAST-K II overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2025-12-31 date: 2025-12-31 date: 2024-04-25 date: 2024-04-25 name: Istituto Ortopedico Rizzoli class: OTHER briefSummary: The majority of patients undergoing total knee arthroplasty are elderly individuals with low functional demands, aiming to alleviate pain. However, there exists a subgroup of younger patients, under the age of 65, with higher functional demands. The purpose of this study is to evaluate the return to sports activities in this patient group following a non-cemented total knee arthroplasty procedure and a specific rehabilitation protocol. The investigators expect that with the use of non-cemented prostheses and a specific rehabilitation protocol, many of these patients will safely resume sports activities. conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: intensive rehabilitation after uncemented TKA measure: number of patients returning to sports activities assessed by questionnaire measure: clinical and functional outcomes measured as the variation in the Knee Society Score sex: ALL minimumAge: 40 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383923 id: BYSYDL2022015 briefTitle: Risk Factors, Prognosis and Prediction Models for Placenta Accreta Without Prior Cesarean Section overallStatus: RECRUITING date: 2023-01-01 date: 2024-12 date: 2024-12 date: 2024-04-25 date: 2024-04-25 name: Peking University Third Hospital class: OTHER briefSummary: 1. Identify the risk factors for Placenta accreta spectrum (PAS) disorders in women without prior caesarean section (CS). |
2. Clarify the prognostic factors of the disease and explore individualized treatment options to improve the prognosis of patients with this type of disease; |
3. Use the cohort's biological sample database to conduct serology, cytology, and histology studies to explore the abnormal uterine immune microenvironment and the impact on uterine spiral artery remodeling in non-scar uterine-placenta accreta disease. conditions: Placenta Accreta Spectrum studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Placenta Accreta Spectrum measure: Amount of bleeding measure: Hemostatic measures measure: hysterectomy measure: blood transfusion volume sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University Third Hospital status: RECRUITING city: Beijing country: China name: Wang Yan, M.D.Ph.D. role: CONTACT phone: 13501282029 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False |
<|newrecord|> nctId: NCT06383910 id: 10.185.1.58 briefTitle: The Effect Of Square Stepping Exercise Training On Cognitive Functions And Quality Of Life In Geriatric Individuals overallStatus: COMPLETED date: 2021-10-12 date: 2023-12-27 date: 2024-01-05 date: 2024-04-25 date: 2024-04-25 name: Pamukkale University class: OTHER briefSummary: This study was designed to investigate the effects of Square-Stepping Exercise Training on cognitive functions and quality of life in geriatric individuals. The volunteer participants in the study were randomly divided into two groups: a square-stepping exercise group and a control group. |
In the study, participants in the exercise training groups received square stepping exercises three days a week for six weeks, while those in the control group did not undergo any training. Both groups were assessed before and six weeks after the training period. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.